DD255477A5 - Verfahren zur herstellung von stabilisierten menschlichen gewebe-plasminogen-aktivator-zusammensetzungen - Google Patents

Verfahren zur herstellung von stabilisierten menschlichen gewebe-plasminogen-aktivator-zusammensetzungen Download PDF

Info

Publication number
DD255477A5
DD255477A5 DD86297695A DD29769586A DD255477A5 DD 255477 A5 DD255477 A5 DD 255477A5 DD 86297695 A DD86297695 A DD 86297695A DD 29769586 A DD29769586 A DD 29769586A DD 255477 A5 DD255477 A5 DD 255477A5
Authority
DD
German Democratic Republic
Prior art keywords
item
composition
arginine
argininium
concentration
Prior art date
Application number
DD86297695A
Other languages
German (de)
English (en)
Inventor
William F Bennett
Stuart E Builder
Larry A Gatlin
Original Assignee
Kkk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25205495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD255477(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kkk filed Critical Kkk
Publication of DD255477A5 publication Critical patent/DD255477A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DD86297695A 1985-12-17 1986-12-16 Verfahren zur herstellung von stabilisierten menschlichen gewebe-plasminogen-aktivator-zusammensetzungen DD255477A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/811,081 US4777043A (en) 1985-12-17 1985-12-17 Stabilized human tissue plasminogen activator compositions

Publications (1)

Publication Number Publication Date
DD255477A5 true DD255477A5 (de) 1988-04-06

Family

ID=25205495

Family Applications (1)

Application Number Title Priority Date Filing Date
DD86297695A DD255477A5 (de) 1985-12-17 1986-12-16 Verfahren zur herstellung von stabilisierten menschlichen gewebe-plasminogen-aktivator-zusammensetzungen

Country Status (23)

Country Link
US (2) US4777043A (fi)
EP (1) EP0228862B1 (fi)
JP (2) JPH0714886B2 (fi)
KR (1) KR950010322B1 (fi)
AT (1) ATE79273T1 (fi)
AU (1) AU600246B2 (fi)
DD (1) DD255477A5 (fi)
DE (2) DE3686410T2 (fi)
DK (1) DK174203B1 (fi)
ES (1) ES2044840T3 (fi)
FI (1) FI88873C (fi)
FR (1) FR2591485B1 (fi)
GB (1) GB2184354B (fi)
GR (1) GR3006078T3 (fi)
HU (1) HU200101B (fi)
IE (1) IE59060B1 (fi)
IL (1) IL80904A (fi)
MY (1) MY102185A (fi)
NO (1) NO168988C (fi)
NZ (1) NZ218612A (fi)
PH (1) PH24716A (fi)
PT (1) PT83933B (fi)
ZA (1) ZA869457B (fi)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE83153T1 (de) * 1985-09-10 1992-12-15 Eisai Co Ltd Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung.
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
EP0317376B2 (fr) * 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
HU206367B (en) * 1988-04-30 1992-10-28 Sandoz Ag Process for producing acid addition salts of steroid carboxylic acid-amidated taurine and glycine, as well as pharmaceutical compositions comprising such salts
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
US6207151B1 (en) * 1989-09-21 2001-03-27 Mitsui Chemicals Inc. Aqueous solution of t-PA
JP2520975B2 (ja) * 1989-09-21 1996-07-31 三井東圧化学株式会社 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
DE19606551C2 (de) * 1996-02-22 2000-06-08 Basotherm Gmbh rt-PA zur Prävention des Nachstars nach Kataraktoperation
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
DE60009926T2 (de) * 1999-08-17 2005-04-07 Novo Nordisk Health Care Ag Stabilisierung von gefriergetrocknetem kuchen
PT1226269E (pt) 1999-11-04 2003-11-28 Genentech Inc Ensaio de hplc de fase reversa para activadores de plasminogenio
AU2001244584B2 (en) * 2000-03-31 2006-01-19 Kirin Pharma Kabushiki Kaisha Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability
US20030077682A1 (en) * 2001-09-07 2003-04-24 Hung Paul Porwen Human tissue urokinase type plasminogen activator formulation
US20110179558A1 (en) * 2009-07-29 2011-07-28 International Enviroguard Systems, Inc. Breathable Protective Fabric and Garment
KR20150128857A (ko) * 2013-03-14 2015-11-18 알러간, 인코포레이티드 지속된-방출 전달의 조성물 및 제조 공정 동안 단백질을 안정화시키는 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK98833C (da) * 1961-04-25 1964-05-25 Novo Terapeutisk Labor As Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger.
DE3273732D1 (en) * 1982-12-30 1986-11-20 Kowa Co Method of producing a tissue plasminogen activator and composition comprising same
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
EP0199574B1 (en) * 1985-04-22 1991-10-23 Genentech, Inc. Human tissue plasminogen activator mutants, methods and intermediates therefor, and compositions using such mutants
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
AT391812B (de) * 1985-05-28 1990-12-10 Wellcome Found Verfahren zur herstellung einer parenteralen t-pa-loesung
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
ATE83153T1 (de) * 1985-09-10 1992-12-15 Eisai Co Ltd Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung.
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
JPS62120321A (ja) * 1985-11-20 1987-06-01 Eisai Co Ltd ｔＰＡ含有医薬組成物
JPS62283932A (ja) * 1986-05-29 1987-12-09 Green Cross Corp:The 組織プラスミノ−ゲンアクチベ−タの乾燥製剤

Also Published As

Publication number Publication date
PH24716A (en) 1990-10-01
NO865079D0 (no) 1986-12-16
FI865159A (fi) 1987-06-18
ES2044840T3 (es) 1994-01-16
HU200101B (en) 1990-04-28
NZ218612A (en) 1989-07-27
MY102185A (en) 1992-04-30
DK605786A (da) 1987-06-18
KR870005647A (ko) 1987-07-06
FR2591485B1 (fr) 1989-07-28
IL80904A (en) 1992-01-15
ATE79273T1 (de) 1992-08-15
JPH07173076A (ja) 1995-07-11
AU600246B2 (en) 1990-08-09
DE3686410D1 (de) 1992-09-17
PT83933A (en) 1987-01-01
HUT42955A (en) 1987-09-28
IE863279L (en) 1987-06-17
EP0228862A2 (en) 1987-07-15
GB8629981D0 (en) 1987-01-28
FI865159A0 (fi) 1986-12-17
DK605786D0 (da) 1986-12-16
DE3686410T2 (de) 1993-02-18
NO865079L (no) 1987-06-18
DE3642960A1 (de) 1987-06-19
PT83933B (pt) 1989-01-17
NO168988C (no) 1992-04-29
ZA869457B (en) 1988-08-31
US4777043A (en) 1988-10-11
EP0228862B1 (en) 1992-08-12
FR2591485A1 (fr) 1987-06-19
GB2184354A (en) 1987-06-24
GB2184354B (en) 1990-04-11
DK174203B1 (da) 2002-09-16
FI88873C (fi) 1993-07-26
KR950010322B1 (ko) 1995-09-14
JPS62164632A (ja) 1987-07-21
FI88873B (fi) 1993-04-15
EP0228862A3 (en) 1988-09-28
IE59060B1 (en) 1993-12-15
JPH0714886B2 (ja) 1995-02-22
IL80904A0 (en) 1987-03-31
NO168988B (no) 1992-01-20
AU6661086A (en) 1987-06-18
US4908205A (en) 1990-03-13
GR3006078T3 (fi) 1993-06-21

Similar Documents

Publication Publication Date Title
DE3686410T2 (de) Stabilisierte zusammensetzungen von menschlichen aktivatoren des gewebeplasminogens.
DE69629209T2 (de) Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose
DE69828330T2 (de) Aktiviertes Protein C Formulierungen
DE60125986T3 (de) Pharmazeutische Zusammensetzungen mit Botulinum Toxin
DE69736177T2 (de) Mit aminosäuren stabilisierte erythropoietinlösung
DE3520228C2 (de) Wasserlösliche bioaktive Trockenfeststoffzusammensetzung, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
DE69729786T2 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
EP0508194B1 (de) Stabilisierte Faktor VIII-Präparationen
DE69532970T3 (de) Sprühgetrocknetes erythropoietin
DE69328519T2 (de) Chondroitinase, Herstellungsverfahren und pharmazeutische Zusammensetzung
DE69334134T2 (de) Wässrige Formulierung enthaltend Menschliches Wachstumshormon
DE69435033T2 (de) Parathormonarzneizusammensetzung
DE69630291T2 (de) Proteinformulierung, die koajulationsfehler viii oder ix in einer saccharose wässriger lösung enthält
EP0733702B1 (de) Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
DE60024268T2 (de) Zusammensetzungen mit stabilem faktor viii
DE3400413C2 (fi)
DE3729863A1 (de) Stabilisierte erythropoietin-lyophilisate
DE60009529T2 (de) Pharmazeutische zusammensetzung aus fibrinolytischem mittel
CH665356A5 (de) Pharmazeutische formulierung.
EP0855917A1 (de) Stabile pharmazeutische darreichungsformen enthaltend parathormon
US5034225A (en) Stabilized human tissue plasminogen activator compositions
DE69420872T2 (de) Hgh enthaltende pharmazeutische zubereitungen
EP0746334B1 (de) Pharmazeutisches präparat enthaltend plasminogenaktivatoren
DE60009926T2 (de) Stabilisierung von gefriergetrocknetem kuchen
DE69101784T2 (de) Stabilisierte zusammensetzung enthaltend ein fibroblastwachstumsfaktor.

Legal Events

Date Code Title Description
IF04 In force in the year 2004

Expiry date: 20061217